Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib versus high-dose imatinib after progression on imatinib 400 mg in GIST
2006-004309-24Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Sunitinib 37.5 mg daily with Imatinib 800 mg daily (2 arms). Primary endpoint: Progression-free survival. Started Feb 2007; status: completed.
02
Drugs
sunitinibimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2006-004309-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004309-24.